Navigation Links
Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
Date:5/19/2010

PRINCETON, N.J., May 19 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

"There is an increasing awareness that IBS results in part from an inflammatory cascade in the GI tract, which makes it amenable to treatment with topically active steroids such as oral BDP," said Christopher J. Schaber, Ph.D., President and Chief Executive Officer of Soligenix.  "This potentially expands the available treatment options for IBS.  The granting of the US patent for BDP in IBS further demonstrates its potential novelty and utility in treating inflammatory GI diseases."

Dr. Schaber continued, "This is part of our strategy of broadening our intellectual property platform in inflammatory gastrointestinal diseases with oral BDP and other topically active steroids.  We believe that our oral BDP formulations will have utility in other inflammatory GI diseases as well such as Graft-versus-Host disease (GVHD), radiation enteritis, and Crohn's disease."

In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to Soligenix, the Company also benefits from orphan drug designations in the US and in Europe on orBec® for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclus
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 In ... and sustainability, the Consulate General of Switzerland in New ... boat, Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... of its DeepWater Expedition 2013 tour with scientists on ... by Capitain Gérard d’Aboville, runs exclusively on energy from ...
(Date:6/18/2013)... Demanding industrial and environmental conditions are no ... and Glass Ball Lenses, now available in an extensive ... , of Philadelphia , PA. , Optical Ball Lenses ... beams without the need for direct physical contact. That’s ... mohs) make it the ideal choice for fiber-optic applications ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 Nasseo, ... 2013 Innovation Challenge Winner out of hundreds of applicants ... its spring Arizona Innovation Challenge . The Arizona ... country for a technology commercialization challenge, granting a financial ... most promising technology ventures. Nasseo’s state of the art ...
(Date:6/18/2013)... ATLANTA , June 18, 2013  regulated information ... Jeff Klauk today announced the launch of ... their loved ones. The Pledge ... take a stand and make a personal commitment to ... with their health care team and additional partial-onset seizure ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... Calif., Jan. 12 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... have successfully demonstrated the,performance of the company,s ... of the platform,s ongoing alpha testing program. ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and manufacturer of the patented anti-cancer biotech product,Endu ... preliminary revenue,and earnings for the full year of ... preliminary data for the fourth quarter, Simcere expects ...
... PHOENIX, Jan. 9 Houlihan Smith & Co., ... non-control equity investment,into Sottera, Inc. d/b/a NJOY, as ... Chairman of Houlihan Smith & Company, Inc. ... Reginald McGaugh.,Terms were not disclosed. , ...
Cached Biology Technology:WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2
(Date:6/19/2013)... In fall 2012, the European Medicines Agency (EMA) ... the first ever gene therapy for clinical use ... company, had developed AAV-LPL S447X for the treatment ... lipase deficiency (LPLD) which affects approximately one or ... causes severe, life-threatening inflammations of the pancreas. Afflicted ...
(Date:6/18/2013)...  Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
(Date:6/18/2013)... Energy Department,s National Renewable Energy Laboratory (NREL), and ... paper describing a novel cellulose-degrading enzyme from a ... known as the gribble. , Gribbles are ... ability to produce their own enzymes instead of ... they eat. New biomass-degrading enzymes from novel sources ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... Austin-based startup cofounded by Mauro Ferrari, Ph.D., of The ... to improve the effectiveness of anti-cancer agents and other ... through the Texas Emerging Technology Fund (ETF). NMS ... awards, which were announced by Texas Gov. Rick Perry ...
... -- The body,s immune system hates strangers. When its ... This is the problem when people with type ... cells from a donor pancreas produce robust amounts of ... insulin therapy. However, the immune system tries to kill ...
... of birth, mouse ovaries are essentially a bag full ... This key time in ovarian development establishes the population ... cohort of follicles. If follicles fail to form, the ... for follicular development. Several factors key to follicular formation ...
Cached Biology News:Texas invests record $3.5 million in startup cofounded by UT's Mauro Ferrari 2New technique eliminates toxic drugs in islet transplant in diabetic mice 2December 2008 highlights from Biology of Reproduction 2